Sign in

CIK 0001158780

  • Non-accelerated filer
  • Smaller reporting company
Ticker
PLUR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Jun 30
Incorporated
NV
Entity type
Operating
EIN
980351734
Phone
+972 747107171
Business address
MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA, Israel
Former names
PLURISTEM THERAPEUTICS INC, PLURISTEM LIFE SYSTEMS INC, AI SOFTWARE INC
  1. 4 Grant or award Director acquired 20,000 shares (grant or award)
  2. 4 Grant or award Director acquired 20,000 shares (grant or award)
  3. 4 Grant or award Director acquired 20,000 shares (grant or award)
  4. 4 Grant or award Director acquired 20,000 shares (grant or award)
  5. 4 Grant or award Chief Financial Officer acquired 100,000 shares (grant or award)
  6. 4 Grant or award CEO & President acquired 1,000,000 shares (grant or award)
  7. 4 Grant or award Executive Chairman acquired 1,000,000 shares (grant or award)
  8. 4 Open-market buy 10% owner bought 65,771 shares at an average $9.24 ($607,924)
  9. 4 Open-market buy 10% owner bought 121,926 shares at $9.03 ($1,100,992)
  10. 4 Open-market buy 10% owner bought 81,198 shares at $8.46 ($686,935)
  11. 4 Open-market buy 10% owner bought 49,396 shares at $8.34 ($411,963)
  12. 4 Open-market buy 10% owner bought 199,686 shares at an average $8.04 ($1,604,865)
  13. 4 Open-market buy 10% owner bought 700,449 shares at an average $7.61 ($5,328,131)
  14. 3 Insider Initial Statement of Ownership
  15. 4 Open-market buy Director bought 14,286 shares at $0.70 ($10,000)
  16. 4 Open-market buy Co-CEO & Chairman bought 71,429 shares at $0.70 ($50,000)
  17. 4 Open-market buy Co-CEO & President bought 71,429 shares at $0.70 ($50,000)
  18. 4 Open-market buy Director bought 71,429 shares at $0.70 ($50,000)
  19. 4 Open-market buy Director bought 28,571 shares at $0.70 ($20,000)
  20. 4 Open-market buy Director bought 50,000 shares at $0.70 ($35,000)

Page 4 of 18 · 352 filings